Keywords: encysive, thelin, study, meets, endpoints, phase, iii

Encysive's Thelin study meets endpoints

Article | 21 February 2005

A Phase III, 18-week, double-blind safety and efficacy clinical trial of US firm Encysive's Thelin (sitaxsentan sodium) for pulmonary arterial ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

bosentan

Tracleer

Nystatin

Go to drug listing